Zydus Cadila seeks emergency-use nod from DCGI for its Covid-19 vaccine

Pharmaceutical major Zydus Cadila has applied for Emergency Use Authorisation (EUA) seeking DCGI’s approval for the launch of their ZyCoV-D vaccine for 12 years and above.

Sources said that the company has completed third phase clinical trials for the vaccine.

ZyCoV-D is the world’s first DNA vaccine against coronavirus and the fourth to become available in the country. The vaccine is a three-dose vaccine, with jabs to be administered at day 0, day 28, and day 56.

Notably this is the second indigenously developed vaccine after Bharat Biotech’s Covaxin.. The company has said it is also working on a two-dose regimen of this vaccine.

The stability data of the vaccine candidate showed that ZyCoV-D can be stored at 2 to 8 degrees Celsius for long-term use and 25 degrees Celsius for the short term.